Clinical Prediction Model for In-Hospital Rebleeding in Acute Non-Variceal Upper Gastrointestinal Bleeding
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Non-variceal Upper Gastrointestinal Bleeding. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Construction of a Clinical Prediction Model for In-Hospital Rebleeding in Patients With Acute Non-Venous Upper Gastrointestinal Bleeding
Overview
ANVUGIB is a serious condition that can cause symptoms like vomiting blood or passing black stools. Although treatments have improved, about 10% to 30% of patients experience rebleeding shortly after their initial treatment, which increases the risk of death. Currently, doctors use tools like the Glasgow-Blatchford Score, Rockall Score, and AIM65 Score to predict how patients with ANVUGIB might recover. However, these tools are not very effective at identifying patients who are at risk for rebleeding. This study aims to create a new, more accurate prediction model to help doctors identify high-risk patients earlier. The investigators believe that a new predictive model, which combines patient symptoms, lab test results, and imaging findings, will improve the ability to identify patients at high risk of rebleeding compared to existing tools.The goal is to provide doctors with a more reliable tool to guide their decisions, such as when to give preventive treatments or increase monitoring. This could lead to better outcomes and reduce the risk of complications or death. This study uses patient data collected during routine care to develop and test the new model, ensuring the findings are directly applicable to real-world clinical settings.
Primary outcome measures
- relbeeding [Time frame: up to 7 days]
Eligibility criteria
Inclusion criteria
- age exceeding 18 years,
- Clinical diagnosis of Acute Non-Variceal Upper Gastrointestinal Bleeding ,
- patients who underwent endoscopy within 24 hours of admission with confirmation of non-variceal bleeding
Exclusion criteria
- Upper Gastrointestinal Bleeding during hospitalization;
- transfer from other hospitals;
- variceal bleeding;
- lower gastrointestinal bleeding.;
- bleeding attributed to systemic diseases like disseminated intravascular coagulation (DIC) and hematological disorders;
- patients with incomplete clinical data or laboratory test results;
- patients who either requested early discharge or declined gastroscopy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- the Central Hospital of Wuhan — Wuhan
Identifiers
NCT: NCT06697691 · ANVUGIB-2024-001